Morgan Stanley
ELVN icon

Morgan Stanley’s Enliven Therapeutics ELVN Stock Holding History

Morgan Stanley’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.9M Sell
509,928
-8,644
-2% -$367K ﹤0.01% 2859
2026
Q1 		$20.3M Buy
518,572
+106,749
+26% +$2.96M ﹤0.01% 2948
2025
Q4 		$6.34M Buy
411,823
+153,439
+59% +$3.06M ﹤0.01% 3999
2025
Q3 		$5.29M Buy
258,384
+3,536
+1% +$71.3K ﹤0.01% 4104
2025
Q2 		$5.11M Buy
254,848
+173,533
+213% +$3.29M ﹤0.01% 4047
2025
Q1 		$1.6M Sell
81,315
-29,291
-26% -$630K ﹤0.01% 4746
2024
Q4 		$2.49M Sell
110,606
-24,801
-18% -$643K ﹤0.01% 4558
2024
Q3 		$3.46M Buy
135,407
+67,107
+98% +$1.55M ﹤0.01% 4245
2024
Q2 		$1.6M Buy
68,300
+5,203
+8% +$110K ﹤0.01% 4690
2024
Q1 		$1.11M Sell
63,097
-16,424
-21% -$252K ﹤0.01% 4900
2023
Q4 		$1.1M Buy
79,521
+45,551
+134% +$557K ﹤0.01% 4872
2023
Q3 		$464K Buy
33,970
+649
+2% +$10.9K ﹤0.01% 5199
2023
Q2 		$680K Buy
33,321
+15,903
+91% +$321K ﹤0.01% 5053
2023
Q1 		$381K Buy
17,418
+3,231
+23% +$65.7K ﹤0.01% 5407
2022
Q4 		$232K Sell
14,187
-1,129
-7% -$18K ﹤0.01% 5604
2022
Q3 		$140K Sell
15,316
-7,708
-33% -$45.5K ﹤0.01% 5904
2022
Q2 		$112K Sell
23,024
-2,460
-10% -$12K ﹤0.01% 6213
2022
Q1 		$191K Sell
25,484
-57,211
-69% -$377K ﹤0.01% 5948
2021
Q4 		$744K Buy
82,695
+10,033
+14% +$132K ﹤0.01% 5288
2021
Q3 		$1.19M Sell
72,662
-34,596
-32% -$719K ﹤0.01% 4943
2021
Q2 		$3.39M Buy
107,258
+26,676
+33% +$827K ﹤0.01% 4172
2021
Q1 		$2.72M Buy
80,582
+78,531
+3,829% +$3.99M ﹤0.01% 4010
2020
Q4 		$181K Buy
2,051
+1,815
+769% +$152K ﹤0.01% 5642
2020
Q3 		$19K Sell
236
-1,006
-81% -$90.7K ﹤0.01% 6087
2020
Q2 		$136K Sell
1,242
-34,847
-97% -$3.9M ﹤0.01% 5250
2020
Q1 		$2.31M Buy
+36,089
New +$2.3M ﹤0.01% 3236

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Morgan Stanley's ELVN Position: Q2 2026 in Review

Morgan Stanley reduced its Enliven Therapeutics (ELVN) stake by 1.7% in Q2 2026, selling an estimated $367K and leaving 509,928 shares worth $25.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2859.

Morgan Stanley first reported a position in ELVN in Q1 2020 and has held it in 26 quarters since. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Morgan Stanley held 509,928 shares of Enliven Therapeutics worth $25.9M as of Q2 2026.
  • Morgan Stanley sold 8,644 Enliven Therapeutics shares in Q2 2026, an estimated $367K.
  • Enliven Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2859 holding.
  • Morgan Stanley first reported a position in Enliven Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • 211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.